



**Alliance for Clinical Trials in Oncology**  
**Friday, November 7, 2014**  
**Loews Hotel Chicago O'Hare**  
**8 am – 12:30 pm**

**Leukemia / Leukemia Correlative Sciences Committee Meeting Agenda**

Chair: Richard M. Stone, MD and Guido Marcucci, MD  
 Vice-Chairs: John Byrd, MD; Tom Shea, MD and Wendy Stock, MD, PhD

**Update: Alliance Data Center Changes**

Beth Kiefer and Marcia Wilson (8-815)

**Update: Faculty Statisticians**

Susan Geyer (815-825)

**Update: Alliance Leukemia Correlative Sciences**

Guido Marcucci (825-835)  
 John Byrd

**ASH Abstract: CALGB 10403 results (pedi-like rx for AYA ALL)**

Wendy Stock (835-850)

**ASH Abstract: CAGB 10801 results (chemo + dasatinib for CBF AML)**

Guido Marcucci (850-905)

**Molecular Analysis of ALL**

Kathryn Roberts (905-920)

**Protocol Review**

Category	Study #	Study Title	Study Chair	Presenter
Active	E1910	Chemo +/- blinatumumab in middle aged adults with pre-B-ALL	M. Litzow M. Wieduwilt, (A)	M. Wieduwilt (920-930)
Active	C10701	Chemo +dasatinib f/b transplant for Ph+ ALL	M. Wetzler	M. Wetzler (930-940)
In Development		PH+ ALL working groups concepts	M. Wetzler	M. Wetzler (940-955)
In Development		Ph il1 successor to 10403:	D. DeAngelo	D. DeAngelo (955-1010)
CTEP Approved	S1318	Blinatumumamab plus POMP in PH- ALL, age >70	A.Advani TBD (A)	R. Stone (1020-1025)

<b>Active</b>	E1910	FCR v ibrutinib in younger CLL	T. Shanafelt J. Bariantos (A)	J. Bariantos (1025-1035)
<b>Active</b>	A041202	Ibrutinib v ibrutinib/rituximab v bendamustine/rituximab in older adults with untreated CLL	J. Woyach	J. Woyach (1035-1045)
<b>In Development</b>		Trial for relapsed CLL	J. Brown	J. Brown (1045-11)
<b>Active</b>	E2905	Revlimid alone +/- Procrit in low or inter-1 risk MDS & symp anem	A. List	R. Stone (11-1105)
<b>LBA ASH abstract</b>	S1117	Rand ph II aza+len vs aza vs aza+vorin in MDS/CMML	M. Sekeres T. Odenike (A)	T. Odenike (1105-1125)
<b>In Development</b>		Potential MDS trial designs		T. Odenike, M. Wieduwilt (1105-1125)
<b>Active</b>	CTSU	S1203: Rnd phIII for AML < 60: 1A & SAHA vs 1A vs 7+3 (DNR90)	G. Garcia-Manero D. Rizzeri (A)	D. Rizzeri (1125-1135)
<b>In Development</b>	C10801 successor	Chemo/dastanib/bortezomib in CBF AML	G. Marcucci	G. Marcucci (1135-1150)
<b>In Development</b>		Older AML WG	G. Uy, H. Klepin	G. Uy, H. Klepin (1150-1210)
<b>Active</b>		BMT CTN MDS transplant	S. Devine	S.Devine (1210-1220)
<b>Completed</b>	C10603	Re-analysis plan for C10603	R. Stone	R. Stone (1220-1230)
	<b>LEUKEMIA CORRELATIVE SCIENCES</b>			
<b>Active</b>	9665-10	The CALGB leukemia tissue bank	M. Caligiuri	G. Marcucci
<b>Active</b>	9862-02	Molecular genetic features of acute leukemia	W. Stock	W. Stock
<b>Active</b>	20202-02	Assessment of novel molecular markers in AML	C. Bloomfield	G Marcucci
<b>Active</b>	20203-00	Molecular markers of CLL	J. Byrd	J. Byrd
<b>Active</b>	20206-00	NK cell recognition & lysis of autologous blasts in AML pts	D. Benson	G. Marcucci
<b>Active</b>	20501-01	LTB: MDR protein gene polymorphisms in AML	M. Baer	M. Baer
<b>Active</b>	20502-00	LTB: Molecular genetic studies of AML with normal cytogenetics	G. Marcucci	G. Marcucci
	20801-00	LTB: Identification of target genes for dx and prognosis of AML	J. Rowley	G. Marcucci